amantadine

February 21, 2017February 21, 2017

#ACTRIMS2017 – Phase 2 Trial Data Shows Better Walking Speeds in MS Patients Using ADS-5102

News

Results from a Phase 2 proof-of-concept study of ADS-5102 (amantadine HCl), showing that multiple sclerosis patients given the extended-release oral treatment improved their walking speed, will be presented at ACTRIMS 2017 this week. Findings ... Read more

February 8, 2017February 8, 2017

MS Alphabet: Abnormal reflexes, ACTH, Amantadine and Other ‘A’ Words

Columns, MS in Moderation, a column by Tamara Sellman

MS Alphabet When it comes to multiple sclerosis, mastering your own understanding of the disease means you need to mind your P’s and Q’s, dot your ... Read more

June 17, 2016June 17, 2016

Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties

News

Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, in multiple sclerosis (MS) patients ... Read more

October 15, 2015October 21, 2015

Adamas Reports Walking Improvement in MS Models with ADS-5102 (Amantadine HCl)

News

Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the ... Read more

Pin It on Pinterest